Dawson James initiated coverage on Rockwell Medical RMTI with a Market Outperform rating and a $12 price target.
Dawson James commented, "We arrive at our target valuation via a combination of methodologies, including DCF and our standardized CAGR valuation approach. Our confidence in RMTI shares achieving our target valuation is derived from the company's demonstrated successful execution of its base business strategy, which targets the nearly 400,000 ESRD patients in the US and approximately 2MM worldwide that require hemodialysis."
Rockwell Medical closed at $7.19 on Monday.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in